Juno Therapeutics

Juno Therapeutics Inc
Public
Traded as NASDAQ: JUNO[1]
Industry Biotechnology
Founded 2013[2]
Headquarters Seattle, WA
Key people

Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)

Mark Gilbert, M.D. (CMO)
Website junotherapeutics.com

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.[2] The company raised $300 million through private funding and a further $265 million through their IPO.

Company History

In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.[3]

In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of Astra Zeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Junos CD19 directed chimeric antigen receptor T cell candidates.[4] In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million.[5] Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas.[6] In June, the company announced it would acquire X-Body for more than $44 million.[7] In June, the company announced a 10-year partnership with Celgene valued at $1 billion.[8] As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno’s therapies around the world. This partnership suprasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014.[9]

In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to compliment its ability to create T cells engineered to target a broad array of cancer targets.[10]

Pipeline

Drug Notes Ref
JCAR014 Currently in Phase I/II trials at the Fred Hutchison Cancer Research Center, tested for relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and acute lymphoblastic leukemia [11]
JCAR015 Designed to treat acute lymphoblastic leukemia, currently in Phase I trials with Memorial Sloan Kettering Cancer Centre, Received Orphan Drug Designation By FDA in November 2014. [12]
JCAR017 Currently in Phase I/II trials at Seattle Children's Hospital, tested for pediatric and young adult relapsed/refractory CD19 positive leukemia [13]
JTCR016 Currently in Phase I for adult acute myeloid leukemia [14]
JCAR023 Currently in Phase I for Pediatric neuroblastoma [14]
JCAR018 Currently in Phase I for non-Hodgkin's lymphoma and acute lymphoblastic leukemia [14]

References

This article is issued from Wikipedia - version of the Thursday, February 11, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.